Endosonics
This article was originally published in The Gray Sheet
Executive Summary
FDA tells firm that its Oracle-Micro coronary balloon angioplasty-imaging catheter premarket approval application requires "additional data presentation and analysis" on patients currently enrolled in clinical trials, the company says. Endosonics previously reported that it submitted data answering all questions raised by the Circulatory System Devices Advisory Panel in conjunction with its April 1993 recommendation against approving the device ("The Gray Sheet" Jan. 10, I&W-12). FDA's new request is due to "recently implemented PMA clinical data presentation requirements," the company says, noting that it will file a PMA amendment containing the data "as soon as possible"
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.